AGA临床实践更新:老年人胰腺囊性病变与肝细胞癌监测专家建议
该专家综述由AGA临床实践更新委员会委托,针对老年人群胰腺囊性病变(PCL)和肝细胞癌(HCC)的监测提出9条最佳实践建议。建议强调根据合并症、预期寿命和患者意愿进行个体化决策,对高龄、稳定且无高危特征的PCL可考虑停止监测,对HCC监测应基于肝硬化病因、肝纤维化分期及预期寿命综合判断。
要点
- 高龄PCL患者若合并症显著(年龄校正Charlson指数≥3-5)且为低风险病变,应不建议常规监测。
- >65岁患者PCL≤15mm且稳定5年、无担忧特征或高危标志,可考虑停止监测。
- HCC监测应基于肝纤维化分期和HCC风险而非单纯年龄,预期寿命<1-2年者应停止监测。
核心结论
- 老年PCL和HCC患者的监测决策应基于个体化评估,权衡获益与风险,结合合并症、预期寿命和患者意愿。
研究设计与样本
- 由AGA临床实践更新委员会委托并批准的专家综述,基于文献回顾和专家意见,未进行系统评价,建议无正式证据质量分级。
主要发现
- 超过70岁患者中PCL偶然发现率超过四分之一,多数惰性但部分可癌变。
- 肝硬化患者HCC风险明确,老年肝硬化人群尤其代谢相关脂肪性肝炎背景下快速增加。
- 现有指南很少明确高龄或衰弱患者何时停止监测。
关键数值与推荐
- 年龄校正Charlson合并症指数≥3-5且为低风险PCL者,建议不常规监测。
- >65岁患者PCL≤15mm且稳定5年(无每年增长≥3mm或2年增长≥6mm)、无担忧特征或高危标志,可考虑停止监测。
- >75岁患者PCL<30mm且稳定5年、无担忧特征或高危标志,应详细讨论继续监测的价值,理解风险后可停止。
- 监测期间出现显著合并症可能无法手术者,即使既往有担忧特征或高危标志但无高级别上皮内瘤变(HGD)或胰腺癌(PC)证据,应讨论停止监测。
- 切除标本含HGD者,建议每6个月MRI/MRCP监测2年,之后每年,直至不再适合完成性胰腺切除术;含PC者按肿瘤指南监测。
临床怎么用
- 对高龄PCL患者应评估合并症和预期寿命,低风险病变避免过度监测。
- HCC监测应基于肝纤维化分期和HCC风险而非年龄,预期寿命<1-2年者停止监测。
- 与患者进行共享决策,讨论停止监测的利弊。
局限性
- 未进行系统评价,建议基于文献回顾和专家意见,无正式证据质量分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: There is a demographic explosion of patients over the age of 60 expected in the United States and worldwide in the next 20 years. Pancreatic cystic lesions (PCLs) are frequently, incidentally identified in more than a quarter of patients above the age of 70 and while the vast majority of these lesions are indolent, some may develop into malignancy. Similarly, while the risk of hepatocellular carcinoma (HCC) is well established in patients with cirrhosis, the proportion of the elderly population with cirrhosis is rapidly expanding, especially in the setting of metabolic dysfunction-associated steatohepatitis. While multiple guidelines define these high-risk populations and provide recommendations on how and when to implement surveillance, these same guidelines rarely specify when to stop surveillance particularly in cases of advanced age or infirmity where the patient's attributable mortality to the surveyed condition or fitness to receive invasive treatments is unclear. In this Clinical Practice Update (CPU), we review evidence-based, patient-centered, practical approaches to assess appropriateness for PCL and HCC surveillance in older individuals, weighing the balance of potential benefit vs harms and the impact of comorbidities and life expectancy on shared decision-making. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through the standard procedures of Clinical Gastroenterology and Hepatology. These best practice advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these best practice advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations Best Practice Advice Statements BEST PRACTICE ADVICE 1: Regardless of age, patients with significant comorbidities (ie, age-adjusted Charlson comorbidity index ≥3-5) with incidental pancreatic cystic lesions (PCLs), particularly low risk PCL, should be counseled against routine PCL surveillance because of the low attributable mortality to pancreatic cancer (PC) and high risks due to intervention in this population. BEST PRACTICE ADVICE 2: Patients >65 years of age with PCLs ≤15 mm in size that are stable for 5 years (no concerning growth rate of 3 mm or more per year or 6 mm or more in 2 years) with no worrisome features or high-risk stigmata (as defined by the International Association of Pancreatology) should be considered for discontinuation of surveillance after detailed shared decision-making with the patient, given the potential increased morbidity with intensive surveillance in this population. BEST PRACTICE ADVICE 3: Patients >75 years of age with PCLs <30 mm, that are stable for 5 years (no concerning growth rate of 3 mm or more per year or 6 mm or more in 2 years) with no worrisome features or high-risk stigmata should have a detailed discussion about the questionable value of ongoing surveillance. Surveillance may be discontinued if they understand the small, population-specific risk of future PC or HGD. BEST PRACTICE ADVICE 4: Development of significant comorbidities, as defined above, which may preclude a surgical resection at any time during the surveillance of PCL, even with prior worrisome features or high-risk stigmata with no evidence of HGD or PC, should lead to discussion about the discontinuation of surveillance. BEST PRACTICE ADVICE 5: Surveillance of PCLs in the remnant pancreas after resection of PCLs, with no evidence of HGD or PC on final pathology can be continued, per the advice in Best Practice Advice statements 2 and 3, inclusive of the surveillance period preceding the resection with a discussion of cessation of surveillance after 5 years of stability. BEST PRACTICE ADVICE 6: In patients with HGD in the resected specimen, surveillance with magnetic resonance imaging with magnetic resonance cholangiopancreatography (MRI/MRCP) is advised (every 6 months for 2 years, then annually), as long as the patients remain surgical candidates for a completion pancreatectomy. In those with PC in the resected specimen, surveillance of the remnant pancreas should be based on current oncologic guidelines and treatment course. In patients with resected HGD or PC, physicians should discuss with their oncology teams the discontinuation of surveillance after 5 years of stability in the remnant pancreas if there is no development of worrisome features or high-risk stigmata. BEST PRACTICE ADVICE 7: Oral antivirals for hepatitis B virus and hepatitis C virus lower hepatocellular carcinoma (HCC) risk, but do not eliminate it. HCC surveillance in older adults with viral hepatitis should be based on fibrosis stage and HCC risk rather than age alone. BEST PRACTICE ADVICE 8: HCC surveillance should be considered for older adults with cirrhosis of any etiology because age increases HCC risk, unless life expectancy is low and is less than 1 to 2 years. BEST PRACTICE ADVICE 9: HCC surveillance should stop if estimated life expectancy is low and is less than 1 to 2 years based on medical comorbidities, impaired functional status, or liver decompensation (eg, Child-Turcotte-Pugh C cirrhosis) where liver transplant is not an option. Shared decision-making with patients can inform HCC surveillance decisions.
引用
- Das KK, Serper M, Vege SS, et al. AGA Clinical Practice Update on Surveillance of Pancreatic Cystic Lesions and Hepatocellular Carcinoma in Older Adults: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42820904. doi:10.1016/j.cgh.2026.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。